Can We Predict Osimertinib Resistance?

Video

There are certain indicators for patients with lung cancer who may progress on osimertinib.

There are certain characteristics that seem to have an effect on acquired resistance to osimertinib (Tagrisso) for patients with EGFR-positive non-small cell lung cancer (NSCLC), explained Niels Reinmuth, MD, PhD, head of the Thoracic Oncology Department at Asklepios Lung Clinic.

Those who progressed on the agent tended to have genetic amplifications or alterations, or changes in their signaling pathways, such as PI3k or BRAF.

While about 20 to 25% of patients can be molecularly identified, there is still work to be done for the rest of patient population.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Recent Videos
Photo of a woman with brown hair and a floral blouse
Photo of a woman with a blue border around the image
2 experts are featured in this series.
2 experts are featured in this series.
Image of a woman with gray hair and glasses in front of a blue Oncology Nursing News background
Photo of a woman with blond wavy hair wearing a blazer in front of a blue Oncology Nursing News background
Photo of a woman with shoulder-length blond hair in front of an Oncology Nursing News backdrop
Image of a woman with white hair in front of an Oncology Nursing News blue background
2 experts are featured in this series.
Image of a man in a suit standing in front of a blue Oncology Nursing News backdrop